Silence Therapeutics price target lowered to $75 from $80 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Silence Therapeutics to $75 from $80 and keeps a Buy rating on the shares post the Q3 report. The company is making steady progress with lead candidates in cardiovascular disease and rare blood cancer to provide a regular cadence of clinical data in 2024, the analyst tells investors in a research note.